IBI354, an anti-HER2 monoclonal antibody-camptothecin derivative conjugate, has shown good anti-tumor activity in platinum-resistant ovarian cancer with HER2 expression of 1+. In our Phase 1 study ...

Scientists have identified a promising new target for cancer treatment by activating a DNA repair enzyme called TDP1, ...

The breakthrough research was conducted by scientists at the Indian Association for the Cultivation of Science (IACS), ...

In a promising development for cancer treatment, researchers have pinpointed a new target by activating a DNA repair enzyme ...

Innovent Biologics Inc. unveiled for the first time safety and efficacy data of IBI-354, an HER2 monoclonal antibody-camptothecin derivative conjugate that shows promising efficacy signals across a ...

1b,d), and even some traditional plant natural products such as podophyllotoxin and camptothecin, both of which became the basis for successful anticancer compounds, are now thought to be produced ...

News, July 26, 2020 New FDA Orphan Drugs The FDA has granted orphan drug designation for 5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin for the treatment of osteosarcoma, 5,7-dihydroxy-3-(4 ...

Some cancer treatments, like camptothecin and its variations, are already used to treat cancers like bowel, pancreas, ovarian, breast, and certain types of lung cancers. This new finding could ...

The anti-tumour effects of Berberine, which possesses multiple pharmacological activities, have gained significant attention ...

Amarex today announced its work on behalf of Gibson Oncology has resulted in an Orphan Drug Designation (ODD) by the United States Food and Drug Admin ...

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing ...